Literature DB >> 1831402

Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid.

R G Moran1, K L Scanlon.   

Abstract

Previous studies from this laboratory indicated that the cytotoxic effects of the fluoropyrimidines on mouse leukemic cells are substantially augmented by folinic acid but that these effects are underestimated in growth inhibition experiments. These results have now been extended to two human tumor cell lines, the WiDr colorectal and T-24 bladder carcinoma cells. In both cell lines, the presence of folinic acid in the medium substantially enhanced the cytotoxicity of a 72-h exposure to either 5-fluorouracil (FUra) or 5-fluoro-2'-deoxyuridine. Folinic acid concentration-response curves for enhancement of the cytotoxicity of FUra to WiDr cells were broad but indicated that response was not maximal until at least 10 microM. Likewise, increased length of exposure to 10 microM folinic acid continuously enhanced the cytotoxicity of a 72-h treatment with FUra, but substantial enhancement was observed even after a 2-h exposure to folinate, and there was a diminished increment of cytotoxicity after 24-h exposure to folinic acid. Surprisingly, folinic acid augmentation of the cytotoxicity of a brief exposure to FUra (4 h) was minimal but enhancement of FUra cytotoxicity became much more pronounced with intervals of exposure to FUra of greater than or equal to 24 h. If these results can be mimicked in vivo without undue host toxicity, our experiments suggest that a substantial improvement in the therapeutic activity of FUra plus folinate would result from prolonged exposure to both agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831402

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; G R Hudes; F Greene; F P LaCreta; J Brennan; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

3.  A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.

Authors:  N B Haas; R J Schilder; S Nash; L M Weiner; R C Catalano; R F Ozols; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

4.  Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.

Authors:  A Guglielmi; C Aschele; F Grossi; L Tixi; A Sobrero
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

5.  Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; A Rogatko; E M Newman; C McAleer; J Brennan; F P LaCreta; G R Hudes; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance.

Authors:  F M Muggia; A Tulpule; A Retzios; F Chen; S Jeffers; C G Leichman; L Leichman; C P Spears; K K Chan
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

7.  A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; J Wendall Goodwin; Stanley P Balcerzak; Wolfram E Samlowski; Heinz-Josef Lenz; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

8.  Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.

Authors:  G A Bjarnason; I G Kerr; N Doyle; M Macdonald; M Sone
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

10.  Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.

Authors:  G J Peters; J Lankelma; R M Kok; P Noordhuis; C J van Groeningen; C L van der Wilt; S Meyer; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.